



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_341_26

You asked:

Under the Freedom of Information Act 2000, I am requesting information regarding the prescribing and dispensing of dupilumab (Dupixent) - all strengths and formulations, however it is classified in your systems, for patients prescribed, approved and dispensed at Betsi Cadwaladr University Health Board.

All requested data should be provided as monthly aggregate counts. Please apply standard NHS statistical disclosure control rules and suppress any patient-count cell below 5. Where indication-attribution is not routinely held in a single source, please provide what is available from your standard reporting and indicate which fields are not held.

1. New patient initiations by indication, monthly. For each calendar month from January 2022 to the date of this request, please provide the number of patients newly approved for / newly initiated on dupilumab at your Health Board, broken down by the indication recorded at the point of approval (for example, as captured on the high-cost-drug / Blueteq approval form).

Data on new initiations are as below; however please note data is not held broken down by indication.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low, we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

2024	Apr	**
	May	7
	Jun	**
	Jul	**
	Aug	7
	Sep	**
	Oct	**

	Nov	**
	Dec	11
2025	Jan	10
	Feb	6
	Mar	8
	Apr	10
	May	8
	Jun	7
	Jul	7
	Aug	**
	Sep	**
	Oct	7
	Nov	**
	Dec	7
2026	Jan	9
	Feb	18
	Mar	7
	Apr	5
	May	10
	Jun	10

2. Prevalent patient counts by indication, monthly.
For the same period, please provide the total number of patients receiving ongoing dupilumab treatment at each month-end, broken down by the same indication categories as Q1.

Please find the patient counts below from January 2022 to June 2026.

Please note that individual conditions are not recorded on pharmacy systems. Therefore, we are unable to provide data broken down by indications.

Patient Count									
2022		2023		2024		2025		2026	
Jan	13	Jan	64	Jan	65	Jan	117	Jan	132
Feb	12	Feb	37	Feb	95	Feb	98	Feb	100
Mar	16	Mar	57	Mar	94	Mar	90	Mar	142
Apr	21	Apr	56	Apr	60	Apr	124	Apr	123
May	27	May	68	May	110	May	112	May	123
Jun	27	Jun	63	Jun	81	Jun	117	Jun	124
Jul	31	Jul	55	Jul	105	Jul	122		
Aug	35	Aug	76	Aug	81	Aug	114		
Sep	55	Sep	65	Sep	100	Sep	94		
Oct	24	Oct	74	Oct	89	Oct	119		
Nov	64	Nov	76	Nov	81	Nov	100		
Dec	61	Dec	52	Dec	86	Dec	99		

3. Total dispensed volume and spend, monthly. For the same period, please provide the total monthly dispensed quantity of dupilumab, broken down by strength and pack/device type (e.g. 200mg and 300mg pre-filled pen and pre-filled syringe packs), and the total monthly spend (£, ex VAT).

I appreciate that actual contracted/net unit prices may be considered commercially sensitive. If you consider the spend figure exempt (e.g. under s.43), I would be grateful if you would instead provide, in order of preference:

- (a) spend calculated at published list / drug-tariff price; or**
- (b) spend in banded ranges; or**
- (c) the dispensed volumes alone, by strength and pack size.**

(c) Please find volume data below from January 2022 to June 2026.

Volume	DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Pen	DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Syringe	DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Pen	DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Syringe
2022	Volume			
Jan	2	0	30	30
Feb	4	0	28	24
Mar	12	0	88	72
Apr	0	0	70	42
May	0	0	75	68
Jun	6	0	114	22
Jul	6	0	124	30
Aug	0	0	144	40
Sep	15	2	220	60
Oct	6	2	98	2
Nov	0	2	290	48
Dec	36	0	239	62
2023	Volume			
Jan	12	2	283	28
Feb	9	4	128	28
Mar	14	6	218	52
Apr	18	2	226	44
May	16	4	254	55
Jun	14	8	218	64
Jul	10	4	196	29
Aug	6	7	274	67
Sep	31	11	194	60
Oct	30	4	284	52
Nov	24	2	304	55
Dec	14	16	182	46
2024	Volume			
Jan	24	6	244	52
Feb	25	13	379	73
Mar	38	0	373	42
Apr	26	6	186	55

May	18	6	467	62
Jun	32	0	296	56
Jul	12	0	404	108
Aug	8	6	348	27
Sep	36	0	344	104
Oct	16	6	384	52
Nov	4	0	340	48
Dec	38	0	326	71

Volume	DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Pen	DUPILUMAB (DUPIXENT) 200 mg in 1.14mL Pre-Filled Syringe	DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Pen	DUPILUMAB (DUPIXENT) 300 mg in 2mL Pre-Filled Syringe
2025	Volume			
Jan	12	6	480	86
Feb	36	0	371	76
Mar	14	0	368	34
Apr	26	14	491	76
May	33	2	414	72
Jun	32	0	468	55
Jul	36	6	465	76
Aug	55	0	435	82
Sep	30	0	416	40
Oct	24	6	484	92
Nov	42	4	402	74
Dec	28	6	393	70
2026	Volume			
Jan	40	2	544	101
Feb	30	2	401	54
Mar	36	7	554	89
Apr	41	0	451	71
May	36	0	488	66
Jun	25	9	509	64